<p>Delphi Financial Group Inc.在第一季度根据最新提交给美国证券交易委员会的 13F 报告，购买了 Cartesian Therapeutics, Inc.（NASDAQ:RNAC - Free Report）的新头寸。该公司购买了公司股票的 660,852 股，价值约 430,000 美元。Cartesian Therapeutics 占 Delphi Financial Group Inc.投资组合的 0.3%，是其第 23 大持仓。截至最近一次提交的美国证券交易委员会报告，Delphi Financial Group Inc.拥有 Cartesian Therapeutics 约 12.26% 的股份。</p>
<p>获取 <strong>Cartesian Therapeutics</strong> 警报：</p>
<p>另外，Hall Laurie J Trustee 在第一季度购买了 Cartesian Therapeutics 的新股份，价值约 34,000 美元。机构投资者和对冲基金拥有公司股票的 86.95%。</p>
<h2>Cartesian Therapeutics 股价下跌 0.2%</h2>
<p>NASDAQ RNAC 股票周二交易中下跌 0.04 美元，报 16.78 美元。该公司的交易量为 399,320 股，相比平均交易量 88,681 股。Cartesian Therapeutics, Inc.的 12 个月最低价为 11.66 美元，最高价为 42.60 美元。该公司的 50 天移动平均价为 25.75 美元，200 天移动平均价为 22.34 美元。</p>
<p>Cartesian Therapeutics（NASDAQ:RNAC - 获取免费报告）最近公布了其截至 5 月 8 日的财报。该公司报告本季度每股亏损 1.97 美元，超过分析师预期的每股亏损 0.81 美元。该季度公司营收为 584 万美元。作为一个团队，股票分析师预测 Cartesian Therapeutics, Inc.本财年将实现 2.28 美元的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>一些研究公司对 RNAC 发表了意见。Oppenheimer 在 7 月 2 日的报告中将 Cartesian Therapeutics 的评级从 “表现优异” 降至 “市场表现”。Mizuho 在 5 月 24 日的研究报告中对 Cartesian Therapeutics 进行了覆盖。他们给出了 “买入” 评级和 40.00 美元的价格目标。Leerink Partnrs 在 4 月 23 日的研究报告中重申了对 Cartesian Therapeutics 股票的 “表现优异” 评级。SVB Leerink 在 4 月 23 日的报告中对 Cartesian Therapeutics 进行了覆盖。他们给出了 “表现优异” 评级和 39.00 美元的目标价。最后，Needham &amp; Company LLC 在周一的报告中重申了对 Cartesian Therapeutics 股票的 “买入” 评级，并给出了 42.00 美元的价格目标。一位投资分析师对该股票进行了持有评级，六位分析师对该公司股票给出了买入评级。根据 MarketBeat.com 的数据，Cartesian Therapeutics 的平均评级为 “中度买入”，共识目标价为 43.83 美元。</p>
<p><strong>查看我们关于 RNAC 的最新股票报告</strong></p>
<h2>Cartesian Therapeutics 简介（免费报告）</h2>
<p>Cartesian Therapeutics, Inc.是一家临床阶段的生物技术公司，致力于提供用于治疗自身免疫疾病的 mRNA 细胞疗法。该公司正在开发 Descartes-08，一种自体抗 BCMA RNA 工程嵌合抗原受体 T 细胞疗法，目前正在进行第 2b 期临床开发，用于治疗全身性重症肌无力，以及用于其他自身免疫疾病的骨髓瘤自动免疫篮试验患者。</p>
<h2>参见</h2>
<ul>
<li>我们喜欢的五只股票，比 Cartesian Therapeutics 更好</li>
<li>如何最有效地使用 MarketBeat 盈利筛选器</li>
<li>3 只内部买入股票，现在加入您的观察名单</li>
<li>如何找到被低估的股票</li>
<li>Commvault 股票：AI 网络安全巨头准备再次翻倍</li>
<li>什么是债券市场假日？如何投资和交易</li>
<li>Intuit 股票准备飙升：RBC 看到 GenAI 带来巨大上涨</li>
</ul>
<p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 赚取 1129% 利润的交易员公布新的人工智能（来自纪念碑交易联盟）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzAy"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Cartesian Therapeutics？</h2>
<p>在考虑购买 Cartesian Therapeutics 之前，您需要听到这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Cartesian Therapeutics 不在名单上。</p>
<p>尽管 Cartesian Therapeutics 目前在分析师中有 “中度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

RNAC

<p>Delphi Financial Group Inc. 已经在 Cartesian Therapeutics, Inc. 中获得了新的持仓。该公司购买了该公司价值约 $430,000 的 660,852 股股票。Cartesian Therapeutics 是一家临床阶段的生物技术公司，致力于开发用于自身免疫性疾病的 mRNA 细胞疗法。该股票的 12 个月最低价为 $11.66，最高价为 $42.60</p>

<p>Delphi Financial Group Inc. purchased a new position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 660,852 shares of the company's stock, valued at approximately $430,000. Cartesian Therapeutics comprises 0.3% of Delphi Financial Group Inc.'s investment portfolio, making the stock its 23rd biggest holding. Delphi Financial Group Inc. owned about 12.26% of Cartesian Therapeutics as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Delphi Financial Group Inc.在第一季度根据最新提交给美国证券交易委员会的 13F 报告，购买了 Cartesian Therapeutics, Inc.（NASDAQ:RNAC - Free Report）的新头寸。该公司购买了公司股票的 660,852 股，价值约 430,000 美元。Cartesian Therapeutics 占 Delphi Financial Group Inc.投资组合的 0.3%，是其第 23 大持仓。截至最近一次提交的美国证券交易委员会报告，Delphi Financial Group Inc.拥有 Cartesian Therapeutics 约 12.26% 的股份。</p>
</div><p>Get <strong>Cartesian Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cartesian Therapeutics</strong> 警报：</p>
</div><p>Separately, Hall Laurie J Trustee bought a new stake in Cartesian Therapeutics in the 1st quarter valued at about $34,000. Institutional investors and hedge funds own 86.95% of the company's stock.</p>
<div class="lb-trans"><p>另外，Hall Laurie J Trustee 在第一季度购买了 Cartesian Therapeutics 的新股份，价值约 34,000 美元。机构投资者和对冲基金拥有公司股票的 86.95%。</p>
</div><h2>Cartesian Therapeutics Trading Down 0.2 %</h2>
<div class="lb-trans"><h2>Cartesian Therapeutics 股价下跌 0.2%</h2>
</div><p>Shares of NASDAQ RNAC traded down $0.04 during trading on Tuesday, reaching $16.78. The company had a trading volume of 399,320 shares, compared to its average volume of 88,681. Cartesian Therapeutics, Inc. has a 12-month low of $11.66 and a 12-month high of $42.60. The business's 50-day moving average is $25.75 and its 200 day moving average is $22.34.</p>
<div class="lb-trans"><p>NASDAQ RNAC 股票周二交易中下跌 0.04 美元，报 16.78 美元。该公司的交易量为 399,320 股，相比平均交易量 88,681 股。Cartesian Therapeutics, Inc.的 12 个月最低价为 11.66 美元，最高价为 42.60 美元。该公司的 50 天移动平均价为 25.75 美元，200 天移动平均价为 22.34 美元。</p>
</div><p>Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($1.97) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($1.16). The firm had revenue of $5.84 million during the quarter. As a group, equities analysts forecast that Cartesian Therapeutics, Inc. will post 2.28 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cartesian Therapeutics（NASDAQ:RNAC - 获取免费报告）最近公布了其截至 5 月 8 日的财报。该公司报告本季度每股亏损 1.97 美元，超过分析师预期的每股亏损 0.81 美元。该季度公司营收为 584 万美元。作为一个团队，股票分析师预测 Cartesian Therapeutics, Inc.本财年将实现 2.28 美元的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of research firms have weighed in on RNAC. Oppenheimer lowered Cartesian Therapeutics from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Tuesday, July 2nd. Mizuho assumed coverage on Cartesian Therapeutics in a research report on Friday, May 24th. They issued a &#34;buy&#34; rating and a $40.00 price objective for the company. Leerink Partnrs reiterated an &#34;outperform&#34; rating on shares of Cartesian Therapeutics in a research report on Tuesday, April 23rd. SVB Leerink assumed coverage on Cartesian Therapeutics in a report on Tuesday, April 23rd. They set an &#34;outperform&#34; rating and a $39.00 target price for the company. Finally, Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $42.00 price objective on shares of Cartesian Therapeutics in a report on Monday. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, Cartesian Therapeutics has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $43.83.</p>
<div class="lb-trans"><p>一些研究公司对 RNAC 发表了意见。Oppenheimer 在 7 月 2 日的报告中将 Cartesian Therapeutics 的评级从 “表现优异” 降至 “市场表现”。Mizuho 在 5 月 24 日的研究报告中对 Cartesian Therapeutics 进行了覆盖。他们给出了 “买入” 评级和 40.00 美元的价格目标。Leerink Partnrs 在 4 月 23 日的研究报告中重申了对 Cartesian Therapeutics 股票的 “表现优异” 评级。SVB Leerink 在 4 月 23 日的报告中对 Cartesian Therapeutics 进行了覆盖。他们给出了 “表现优异” 评级和 39.00 美元的目标价。最后，Needham &amp; Company LLC 在周一的报告中重申了对 Cartesian Therapeutics 股票的 “买入” 评级，并给出了 42.00 美元的价格目标。一位投资分析师对该股票进行了持有评级，六位分析师对该公司股票给出了买入评级。根据 MarketBeat.com 的数据，Cartesian Therapeutics 的平均评级为 “中度买入”，共识目标价为 43.83 美元。</p>
</div><p><strong>View Our Latest Stock Report on RNAC</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 RNAC 的最新股票报告</strong></p>
</div><h2>Cartesian Therapeutics Profile (Free Report)</h2>
<div class="lb-trans"><h2>Cartesian Therapeutics 简介（免费报告）</h2>
</div><p>Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.</p>
<div class="lb-trans"><p>Cartesian Therapeutics, Inc.是一家临床阶段的生物技术公司，致力于提供用于治疗自身免疫疾病的 mRNA 细胞疗法。该公司正在开发 Descartes-08，一种自体抗 BCMA RNA 工程嵌合抗原受体 T 细胞疗法，目前正在进行第 2b 期临床开发，用于治疗全身性重症肌无力，以及用于其他自身免疫疾病的骨髓瘤自动免疫篮试验患者。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Cartesian Therapeutics</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>3 Insider-Buy Stocks to Add to Your Watchlist Now</li>
<li>How to Find Undervalued Stocks</li>
<li>Commvault Stock: AI Cybersecurity Giant Ready to Double Again</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Intuit Stock Ready to Soar: RBC Sees Big Upside with GenAI</li>
</ul>
<div class="lb-trans"><h2>参见</h2>
<ul>
<li>我们喜欢的五只股票，比 Cartesian Therapeutics 更好</li>
<li>如何最有效地使用 MarketBeat 盈利筛选器</li>
<li>3 只内部买入股票，现在加入您的观察名单</li>
<li>如何找到被低估的股票</li>
<li>Commvault 股票：AI 网络安全巨头准备再次翻倍</li>
<li>什么是债券市场假日？如何投资和交易</li>
<li>Intuit 股票准备飙升：RBC 看到 GenAI 带来巨大上涨</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Trader behind 1,129% profit reveals new AI (From Monument Traders Alliance)(Ad)</p>
<div class="lb-trans"><p>→ 赚取 1129% 利润的交易员公布新的人工智能（来自纪念碑交易联盟）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzAy" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8702&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Cartesian Therapeutics right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Cartesian Therapeutics？</h2>
</div><p>Before you consider Cartesian Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Cartesian Therapeutics 之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Cartesian Therapeutics 不在名单上。</p>
</div><p>While Cartesian Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Cartesian Therapeutics 目前在分析师中有 “中度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

德尔菲金融集团公司收购了 Cartesian Therapeutics, Inc.（纳斯达克：RNAC）的新股份